Published in PLoS One on October 10, 2013
Oncolytic virotherapy using herpes simplex virus: how far have we come? Oncolytic Virother (2015) 0.97
Preclinical evaluation of engineered oncolytic herpes simplex virus for the treatment of pediatric solid tumors. PLoS One (2014) 0.85
Neuroblastomas vary widely in their sensitivities to herpes simplex virotherapy unrelated to virus receptors and susceptibility. Gene Ther (2015) 0.83
Gene therapy as a potential tool for treating neuroblastoma-a focused review. Cancer Gene Ther (2016) 0.79
Pediatric cancer gone viral. Part II: potential clinical application of oncolytic herpes simplex virus-1 in children. Mol Ther Oncolytics (2015) 0.78
Rationale and Design of a Phase 1 Clinical Trial to Evaluate HSV G207 Alone or with a Single Radiation Dose in Children with Progressive or Recurrent Malignant Supratentorial Brain Tumors. Hum Gene Ther Clin Dev (2017) 0.75
Oncolytic virotherapy for pediatric malignancies: future prospects. Oncolytic Virother (2016) 0.75
Effect of Repeat Dosing of Engineered Oncolytic Herpes Simplex Virus on Preclinical Models of Rhabdomyosarcoma. Transl Oncol (2016) 0.75
Newly Characterized Murine Undifferentiated Sarcoma Models Sensitive to Virotherapy with Oncolytic HSV-1 M002. Mol Ther Oncolytics (2017) 0.75
Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer (2003) 10.88
Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science (1984) 9.64
The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J Clin Oncol (2008) 6.66
Inhibition of focal adhesion kinase decreases tumor growth in human neuroblastoma. Cell Cycle (2010) 2.67
Engineered herpes simplex virus expressing IL-12 in the treatment of experimental murine brain tumors. Proc Natl Acad Sci U S A (2000) 1.99
Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing. Proc Natl Acad Sci U S A (2001) 1.99
Localization of a binding site for herpes simplex virus glycoprotein D on herpesvirus entry mediator C by using antireceptor monoclonal antibodies. J Virol (2000) 1.98
Comparative usage of herpesvirus entry mediator A and nectin-1 by laboratory strains and clinical isolates of herpes simplex virus. Virology (2004) 1.73
Treatment of intracranial gliomas in immunocompetent mice using herpes simplex viruses that express murine interleukins. Gene Ther (1998) 1.57
N-MYC regulates focal adhesion kinase expression in human neuroblastoma. J Biol Chem (2007) 1.41
Oncolytic treatment and cure of neuroblastoma by a novel attenuated poliovirus in a novel poliovirus-susceptible animal model. Cancer Res (2007) 1.41
Neuroblastoma cell lines contain pluripotent tumor initiating cells that are susceptible to a targeted oncolytic virus. PLoS One (2009) 1.40
Changes over three decades in outcome and the prognostic influence of age-at-diagnosis in young patients with neuroblastoma: a report from the International Neuroblastoma Risk Group Project. Eur J Cancer (2010) 1.30
Augmented MYCN expression advances the malignant phenotype of human neuroblastoma cells: evidence for induction of autocrine growth factor activity. Cancer Res (1990) 1.29
Inverse relationship between trk expression and N-myc amplification in human neuroblastomas. Cancer Res (1992) 1.27
Enhancement of replication of genetically engineered herpes simplex viruses by ionizing radiation: a new paradigm for destruction of therapeutically intractable tumors. Gene Ther (1998) 1.26
Engineered herpes simplex viruses efficiently infect and kill CD133+ human glioma xenograft cells that express CD111. J Neurooncol (2009) 1.20
Triple gene-deleted oncolytic herpes simplex virus vector double-armed with interleukin 18 and soluble B7-1 constructed by bacterial artificial chromosome-mediated system. Cancer Res (2005) 1.19
B-myb promoter retargeting of herpes simplex virus gamma34.5 gene-mediated virulence toward tumor and cycling cells. J Virol (1999) 1.18
Radiation-induced cellular DNA damage repair response enhances viral gene therapy efficacy in the treatment of malignant pleural mesothelioma. Ann Surg Oncol (2006) 1.10
Neuroblastoma: changing incidence and survival in young people aged 0-24 years. A report from the North of England Young Persons' Malignant Disease Registry. Med Pediatr Oncol (2001) 1.06
Staging and treatment of neuroblastoma. Cancer (1980) 1.05
Engineered herpes simplex virus expressing bacterial cytosine deaminase for experimental therapy of brain tumors. Cancer Gene Ther (2006) 1.05
Photodynamic therapy augments the efficacy of oncolytic vaccinia virus against primary and metastatic tumours in mice. Br J Cancer (2011) 1.03
Treatment of metastatic neuroblastoma with systemic oncolytic virotherapy delivered by autologous mesenchymal stem cells: an exploratory study. Cancer Gene Ther (2010) 1.02
Oncolytic herpes simplex virus mutants are more efficacious than wild-type adenovirus Type 5 for the treatment of high-risk neuroblastomas in preclinical models. Pediatr Blood Cancer (2005) 1.01
Herpes simplex virus oncolytic therapy for pediatric malignancies. Mol Ther (2009) 0.99
Ionizing radiation activates late herpes simplex virus 1 promoters via the p38 pathway in tumors treated with oncolytic viruses. Cancer Res (2005) 0.97
Increased oncolytic efficacy for high-grade gliomas by optimal integration of ionizing radiation into the replicative cycle of HSV-1. Gene Ther (2011) 0.93
Targeting pediatric cancer stem cells with oncolytic virotherapy. Pediatr Res (2012) 0.92
Radiation therapy potentiates effective oncolytic viral therapy in the treatment of lung cancer. Ann Thorac Surg (2005) 0.92
Oncolytic adenovirus treatment of a patient with refractory neuroblastoma. Acta Oncol (2010) 0.92
Combined RAR alpha- and RXR-specific ligands overcome N-myc-associated retinoid resistance in neuroblastoma cells. Biochem Biophys Res Commun (2003) 0.90
Molecular analysis of human cancer cells infected by an oncolytic HSV-1 reveals multiple upregulated cellular genes and a role for SOCS1 in virus replication. Cancer Gene Ther (2008) 0.89
The use of a genetically engineered herpes simplex virus (R7020) with ionizing radiation for experimental hepatoma. Gene Ther (2002) 0.89
Sustained cytokine production and immunophenotypic changes in human neuroblastoma cell lines transduced with a human gamma interferon vector. Cancer Gene Ther (1995) 0.88
Synergistic action of oncolytic herpes simplex virus and radiotherapy in pancreatic cancer cell lines. Br J Surg (2010) 0.86
Replication-selective herpes simplex virus type 1 mutant therapy of cervical cancer is enhanced by low-dose radiation. Hum Gene Ther (2002) 0.86
Improved antitumour immunity in murine neuroblastoma using a combination of IL-2 and IL-12. Br J Cancer (2003) 0.84
Neuroblastoma regression and immunity induced by transgenic expression of interleukin-12. J Pediatr Surg (1999) 0.79
Cellular mechanisms of interleukin-12-mediated neuroblastoma regression. J Pediatr Surg (2003) 0.78
Oncolytic virotherapy for neuroblastoma. Discov Med (2010) 0.78
Human cytomegalovirus infection and expression in human malignant glioma. Cancer Res (2002) 4.58
Subgroup-specific structural variation across 1,000 medulloblastoma genomes. Nature (2012) 4.13
Comparison of plan quality and delivery time between volumetric arc therapy (RapidArc) and Gamma Knife radiosurgery for multiple cranial metastases. Neurosurgery (2014) 3.38
Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure. Blood (2012) 2.46
Inhibition of cystine uptake disrupts the growth of primary brain tumors. J Neurosci (2005) 2.17
Laparoscopic cholecystectomy for biliary dyskinesia in children: frequency increasing. J Pediatr Surg (2013) 2.00
Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors. Blood (2013) 1.83
CD133 is a marker of bioenergetic stress in human glioma. PLoS One (2008) 1.63
Enhancement of glioma radiotherapy and chemotherapy response with targeted antibody therapy against death receptor 5. Int J Radiat Oncol Biol Phys (2008) 1.56
Systemic anti-hepatocyte growth factor monoclonal antibody therapy induces the regression of intracranial glioma xenografts. Clin Cancer Res (2006) 1.54
Loss of protein inhibitors of activated STAT-3 expression in glioblastoma multiforme tumors: implications for STAT-3 activation and gene expression. Clin Cancer Res (2008) 1.52
p27Kip1 and cyclin D1 are necessary for focal adhesion kinase regulation of cell cycle progression in glioblastoma cells propagated in vitro and in vivo in the scid mouse brain. J Biol Chem (2004) 1.48
Risk factors for conversion to permanent ventricular shunt in patients receiving therapeutic ventriculostomy for traumatic brain injury. Neurosurgery (2011) 1.45
The relationship between INR and development of hemorrhage with placement of ventriculostomy. J Trauma (2011) 1.44
Acid-sensing ion channels in malignant gliomas. J Biol Chem (2003) 1.38
Tristetraprolin down-regulates interleukin-8 and vascular endothelial growth factor in malignant glioma cells. Cancer Res (2008) 1.36
Acquisition of temozolomide chemoresistance in gliomas leads to remodeling of mitochondrial electron transport chain. J Biol Chem (2010) 1.30
Lyn kinase activity is the predominant cellular SRC kinase activity in glioblastoma tumor cells. Cancer Res (2005) 1.29
Glucose metabolism heterogeneity in human and mouse malignant glioma cell lines. J Neurooncol (2005) 1.29
Oncolytic viruses: clinical applications as vectors for the treatment of malignant gliomas. J Neurooncol (2003) 1.28
Focal adhesion kinase enhances signaling through the Shc/extracellular signal-regulated kinase pathway in anaplastic astrocytoma tumor biopsy samples. Cancer Res (2002) 1.26
Increased efficacy of an interleukin-12-secreting herpes simplex virus in a syngeneic intracranial murine glioma model. Neuro Oncol (2005) 1.26
Hitting a moving target: evolution of a treatment paradigm for atypical meningiomas amid changing diagnostic criteria. Neurosurg Focus (2008) 1.26
Therapeutic potential of AZD1480 for the treatment of human glioblastoma. Mol Cancer Ther (2011) 1.22
Engineered herpes simplex viruses efficiently infect and kill CD133+ human glioma xenograft cells that express CD111. J Neurooncol (2009) 1.20
Patterns of failure for glioblastoma multiforme following concurrent radiation and temozolomide. J Med Imaging Radiat Oncol (2011) 1.18
The RNA-binding protein HuR promotes glioma growth and treatment resistance. Mol Cancer Res (2011) 1.16
Surface expression of ASIC2 inhibits the amiloride-sensitive current and migration of glioma cells. J Biol Chem (2006) 1.15
Intratumoral 5-fluorouracil produced by cytosine deaminase/5-fluorocytosine gene therapy is effective for experimental human glioblastomas. Cancer Res (2002) 1.14
Acquisition of chemoresistance in gliomas is associated with increased mitochondrial coupling and decreased ROS production. PLoS One (2011) 1.14
Posttranscriptional control of type I interferon genes by KSRP in the innate immune response against viral infection. Mol Cell Biol (2011) 1.13
Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24-month follow-up. Am J Hematol (2014) 1.13
Recurrent pneumonia in children: a case report and approach to diagnosis. Clin Pediatr (Phila) (2006) 1.12
Oncolytic viral therapy of malignant glioma. Neurotherapeutics (2009) 1.12
Expression signature of IFN/STAT1 signaling genes predicts poor survival outcome in glioblastoma multiforme in a subtype-specific manner. PLoS One (2012) 1.11
Predictors of distant brain recurrence for patients with newly diagnosed brain metastases treated with stereotactic radiosurgery alone. Int J Radiat Oncol Biol Phys (2007) 1.10
Brain metastases. Curr Probl Surg (2004) 1.07
Xanthine oxidase-dependent regulation of hypoxia-inducible factor in cancer cells. Cancer Res (2006) 1.07
Preclinical evaluation of a genetically engineered herpes simplex virus expressing interleukin-12. J Virol (2012) 1.06
Proteomic identification of biomarkers in the cerebrospinal fluid (CSF) of astrocytoma patients. J Proteome Res (2007) 1.06
FAK inhibition decreases cell invasion, migration and metastasis in MYCN amplified neuroblastoma. Clin Exp Metastasis (2012) 1.05
The role of DDX3 in regulating Snail. Biochim Biophys Acta (2011) 1.05
ABT-510, a modified type 1 repeat peptide of thrombospondin, inhibits malignant glioma growth in vivo by inhibiting angiogenesis. Cancer Biol Ther (2007) 1.05
Ketone bodies inhibit the viability of human neuroblastoma cells. J Pediatr Surg (2009) 1.05
Fas engagement increases expression of interleukin-6 in human glioma cells. J Neurooncol (2002) 1.02
Initial treatment of melanoma brain metastases using gamma knife radiosurgery: an evaluation of efficacy and toxicity. Cancer (2004) 1.01
Enhanced inhibition of syngeneic murine tumors by combinatorial therapy with genetically engineered HSV-1 expressing CCL2 and IL-12. Cancer Gene Ther (2005) 1.01
A phase 1 trial of ABT-510 concurrent with standard chemoradiation for patients with newly diagnosed glioblastoma. Arch Neurol (2010) 0.99
Herpes simplex virus oncolytic therapy for pediatric malignancies. Mol Ther (2009) 0.99
Genetically engineered herpes simplex viruses that express IL-12 or GM-CSF as vaccine candidates. Vaccine (2005) 0.98
Health-related quality of life of bosutinib (SKI-606) in imatinib-resistant or imatinib-intolerant chronic phase chronic myeloid leukemia. Leuk Res (2011) 0.98
Protein kinase C isoform antagonism controls BNaC2 (ASIC1) function. J Biol Chem (2002) 0.97
Preclinical evaluation of ex vivo expanded/activated γδ T cells for immunotherapy of glioblastoma multiforme. J Neurooncol (2010) 0.97
Laparoscopic surgery in children with congenital heart disease. J Pediatr Surg (2012) 0.96
Complete response to carboplatin, gemcitabine, and paclitaxel in a patient with advanced metastatic renal medullary carcinoma. Pediatr Blood Cancer (2010) 0.96
Cancer Stem Cells and Pediatric Solid Tumors. Cancers (Basel) (2011) 0.96
Low-density lipoprotein receptor-related protein contributes to the antiangiogenic activity of thrombospondin-2 in a murine glioma model. Cancer Res (2005) 0.95
Twenty years of progress in congenital diaphragmatic hernia at the University of Florida. Am Surg (2003) 0.95
Increased expression of thymidylate synthetase (TS), ubiquitin specific protease 10 (USP10) and survivin is associated with poor survival in glioblastoma multiforme (GBM). J Neurooncol (2006) 0.94
Transcriptional targeting of adenovirally delivered tumor necrosis factor alpha by temozolomide in experimental glioblastoma. Cancer Res (2004) 0.93
MARCKS regulates growth and radiation sensitivity and is a novel prognostic factor for glioma. Clin Cancer Res (2012) 0.93
Radiation dosimetry of 131I-chlorotoxin for targeted radiotherapy in glioma-bearing mice. J Neurooncol (2005) 0.92
Targeting pediatric cancer stem cells with oncolytic virotherapy. Pediatr Res (2012) 0.92
Characterization and immunotherapeutic potential of gammadelta T-cells in patients with glioblastoma. Neuro Oncol (2009) 0.92
Treatment of hepatitis C virus infection. Ann Intern Med (2015) 0.91
Prognostic relevance of cytochrome C oxidase in primary glioblastoma multiforme. PLoS One (2013) 0.91
Mesenteric lipoblastoma: a rare location in children. J Pediatr Surg (2008) 0.90
Synthesis and biological evaluation of paclitaxel-C225 conjugate as a model for targeted drug delivery. Bioconjug Chem (2003) 0.90
Cation selectivity and inhibition of malignant glioma Na+ channels by Psalmotoxin 1. Am J Physiol Cell Physiol (2004) 0.90
CD133 marks a myogenically primitive subpopulation in rhabdomyosarcoma cell lines that are relatively chemoresistant but sensitive to mutant HSV. Pediatr Blood Cancer (2012) 0.90
Persistence of mixed cryoglobulinemia despite cure of hepatitis C with new oral antiviral therapy including direct-acting antiviral sofosbuvir: A case series. Postgrad Med (2015) 0.89
Oncolytic HSV-1 for the treatment of brain tumours. Herpes (2006) 0.89
Dexmedetomidine as rescue drug during awake craniotomy for cortical motor mapping and tumor resection. Anesth Analg (2006) 0.89
Hypoxia Moderates γ(1)34.5-Deleted Herpes Simplex Virus Oncolytic Activity in Human Glioma Xenoline Primary Cultures. Transl Oncol (2012) 0.89
Routine utilization of single-incision pediatric endosurgery (SIPES): a 5-year institutional experience. J Laparoendosc Adv Surg Tech A (2015) 0.89
Feasibility of single-incision pediatric endosurgery for treatment of appendicitis in 415 children. J Laparoendosc Adv Surg Tech A (2012) 0.88